医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

年龄分层下的接触过敏原分布特征与临床意义

Distribution characteristics and clinical significance of exposed allergens in different age groups

摘要目的:评估变应性接触性皮炎(allergic contact dermatitis,ACD)患者斑贴试验阳性率、过敏原分布及其与人口学特征、免疫指标的关联。方法:采用病例回顾研究,纳入2023年6月至2024年6月首都医科大学宣武医院402例临床疑诊ACD患者(女性338例,中位年龄38岁;男性64例,中位年龄43岁),行标准斑贴试验(中国基准系列100项半抗原)及血清总IgE、嗜酸性粒细胞(EOS)检测。组间比较采用卡方检验、 t检验/Mann-Whitney U检验,相关性采用Spearman分析。 结果:402例患者斑贴试验总体阳性率为62.69%(252/402),其中85.71%(216/252)对前21种过敏原敏感;患者以女性(84.26%,182/216)和19~35岁组(36.57%,79/216)为主。主要致敏原为氯化钴(总阳性率22.89%,92/402)和硫酸镍(19.90%,80/402),硫柳汞的重度反应比例(+++)最高(10/16)。男性对卡巴混合物( OR=5.10, P=0.002)和没食子酸辛酯( OR=2.64, P=0.047)的阳性风险显著高于女性。年龄分层显示:36~50岁组氯化钴阳性率异常升高至76.72%(50/65),显著高于其他年龄组(≤18岁:20.00%;19~35岁:21.51%;>50岁:16.13%;均 P<0.05),而>50岁组硫酸镍阳性率最高(20.96%,13/62)。斑贴试验阳性数量、反应强度(平均/最大)与总IgE( r=-0.075~0.063)、嗜酸性粒细胞绝对值及百分比均无显著相关性( P>0.05)。临床诊断中,>50岁组湿疹比例达22.58%(14/62),过敏性皮炎合并ACD最常见(16.67%,36/216)。 结论:硫酸镍与氯化钴为ACD主要致敏原,各年龄组致敏模式相似且与IgE/EOS无关;硫柳汞重度反应比例显著更高,或与含汞制品(如疫苗防腐剂)强致敏性相关;36~50岁组氯化钴阳性率显著升高,提示特殊暴露风险;女性高发或与镍/钴相关制品(饰品、化妆品)接触相关。

更多

abstractsObjective:This study aimed to assess the patch test positivity rate, allergen distribution, and their associations with demographic characteristics and immune indicators in patients with allergic contact dermatitis (ACD).Methods:A retrospective medical record analysis was conducted on 402 patients suspected of ACD (338 females, median age 38 years; 64 males, median age 43 years) seen at Xuanwu Hospital, Capital Medical University between June 2023 and June 2024. Standard patch tests (using 100 haptens from the Chinese baseline series) were administered, and serum total IgE and eosinophil levels were measured. Statistical analyses included chi-square tests, t-tests/Mann-Whitney U tests for group comparisons, and Spearman correlation for associations. Results:The overall patch test positivity rate among the 402 patients was 62.69% (252/402), with 85.71% (216/252) showing sensitivity to the top 21 allergens. Predominantly, the affected individuals were females (84.26%, 182/216) aged 19-35 years (36.57%, 79/216). The primary sensitizers were cobalt chloride (22.89%, 92/402) and nickel sulfate (19.90%, 80/402). The highest proportion of severe reactions (+++) was observed with thimerosal (10/16). Males exhibited significantly higher positive risks for carba mix ( OR=5.10, P=0.002) and octyl gallate ( OR=2.64, P=0.047) compared to females. The age-stratified results revealed that the cobalt chloride positive rate was abnormally increased to 76.72% (50/65) in the 36-50 years age group, a rate significantly higher than those observed in the ≤18 years group (20.00%), the 19-35 years group (21.51%), and the >50 years group (16.13%; all P<0.05). In contrast, the >50 years age group exhibited the highest positive rate for nickel sulfate among all age groups at 20.96% (13/62). No significant correlations were found between the number of positive patch tests, reaction intensity (average/maximum), and total IgE ( r=-0.075-0.063), absolute and percentage of eosinophils ( P>0.05). Clinically, eczema prevalence in the>50 age group was 22.58% (14/62), with ACD complicated by allergic dermatitis being the most common (16.67%, 36/216). Conclusion:Nickel sulfate and cobalt chloride are primary sensitizers for ACD. Sensitization patterns across age groups are similar and unrelated to IgE/EOS levels. The higher incidence of severe reactions to thimerosal may be linked to heightened sensitization to mercury-containing products like vaccine preservatives. The notably increased cobalt chloride positivity in the 36-50 age group suggests a unique exposure risk, while the higher prevalence in females may be associated with contact with nickel/cobalt-containing items such as jewelry and cosmetics.

More
广告
DOI 10.3760/cma.j.cn112150-20250520-00453
发布时间 2025-09-06(万方平台首次上网日期,不代表论文的发表时间)
  • 浏览7
  • 下载0
中华预防医学杂志

中华预防医学杂志

2025年59卷9期

1414-1421页

MEDLINEISTICPKUCSCDCA

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷